独立验证的列线图用于新诊断胶质母细胞瘤患者个体化生存估计:NRG Oncology RTOG 0525和0825
研究利用NRG Oncology RTOG 0525(799例)和0825(555例)两项独立临床试验数据,构建并独立验证用于估计新诊断胶质母细胞瘤患者个体化生存概率的列线图。最终列线图基于Cox比例风险模型,纳入年龄、性别、KPS、切除程度和MGMT甲基化状态等因素,可预测6、12和24个月生存概率,并提供免费软件。
要点
- 基于Cox比例风险模型构建的列线图可个体化估计新诊断胶质母细胞瘤患者6、12和24个月生存概率。
- 增加短期生存概率的因素包括年龄较大、男性、KPS较低、未全切除和MGMT未甲基化。
- 列线图在独立临床试验数据中验证,并提供免费在线计算软件。
核心结论
- 列线图可评估新诊断胶质母细胞瘤患者个体化6、12和24个月生存概率,可能有助于医疗提供者与患者讨论治疗决策和优化治疗策略。
研究设计与样本
- 分析纳入NRG Oncology RTOG 0525试验799例和RTOG 0825试验555例符合条件的随机化新诊断胶质母细胞瘤患者。
- 使用Cox比例风险回归、随机生存森林和递归分割分析评估生存,模型用0525数据开发并用0825数据独立验证。
- 模型采用10折交叉验证进行内部验证,并生成个体预测的6、12和24个月生存概率以衡量预测准确性和校准度。
主要发现
- 最终列线图基于Cox比例风险模型构建。
- 增加较短生存概率的因素包括诊断时年龄较大、男性、KPS较低、未全切除和MGMT未甲基化。
临床怎么用
- 作者认为列线图可能有助于医疗提供者与患者讨论治疗决策和优化治疗策略,并提供免费实施软件:http://cancer4.case.edu/rCalculator/rCalculator.html。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Glioblastoma (GBM) is the most common primary malignant brain tumor. Nomograms are often used for individualized estimation of prognosis. This study aimed to build and independently validate a nomogram to estimate individualized survival probabilities for patients with newly diagnosed GBM, using data from 2 independent NRG Oncology Radiation Therapy Oncology Group (RTOG) clinical trials. METHODS: This analysis included information on 799 (RTOG 0525) and 555 (RTOG 0825) eligible and randomized patients with newly diagnosed GBM and contained the following variables: age at diagnosis, race, gender, Karnofsky performance status (KPS), extent of resection, O6-methylguanine-DNA methyltransferase (MGMT) methylation status, and survival (in months). Survival was assessed using Cox proportional hazards regression, random survival forests, and recursive partitioning analysis, with adjustment for known prognostic factors. The models were developed using the 0525 data and were independently validated using the 0825 data. Models were internally validated using 10-fold cross-validation, and individually predicted 6-, 12-, and 24-month survival probabilities were generated to measure the predictive accuracy and calibration against the actual survival status. RESULTS: A final nomogram was built using the Cox proportional hazards model. Factors that increased the probability of shorter survival included greater age at diagnosis, male gender, lower KPS, not having total resection, and unmethylated MGMT status. CONCLUSIONS: A nomogram that assesses individualized survival probabilities (6-, 12-, and 24-mo) for patients with newly diagnosed GBM could be useful to health care providers for counseling patients regarding treatment decisions and optimizing therapeutic approaches. Free software for implementing this nomogram is provided: http://cancer4.case.edu/rCalculator/rCalculator.html.
引用
- Gittleman H, Lim D, Kattan MW, et al. An independently validated nomogram for individualized estimation of survival among patients with newly diagnosed glioblastoma: NRG Oncology RTOG 0525 and 0825. Neuro Oncol. 2017. PMID: 28453749. doi:10.1093/neuonc/now208
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。